TriSalus Life Sciences (NASDAQ:TLSI) Given "Buy" Rating at Roth Mkm

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at Roth Mkm in a report released on Friday,Benzinga reports. They presently have a $11.00 price objective on the stock. Roth Mkm's price objective would indicate a potential upside of 112.36% from the company's previous close.

Several other analysts have also recently issued reports on TLSI. Northland Securities assumed coverage on TriSalus Life Sciences in a report on Friday, October 25th. They set an "outperform" rating and a $12.50 price objective on the stock. Northland Capmk raised shares of TriSalus Life Sciences to a "strong-buy" rating in a research note on Friday, October 25th. Roth Capital raised shares of TriSalus Life Sciences to a "strong-buy" rating in a research note on Monday, November 11th. Canaccord Genuity Group lowered their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a "buy" rating for the company in a report on Friday, November 15th. Finally, Cantor Fitzgerald initiated coverage on TriSalus Life Sciences in a research note on Tuesday, December 17th. They set an "overweight" rating and a $10.00 price objective on the stock. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $11.79.

TriSalus Life Sciences Price Performance

Shares of TLSI stock traded up $0.02 during trading hours on Friday, hitting $5.18. The stock had a trading volume of 14,302 shares, compared to its average volume of 24,802. The stock has a market capitalization of $157.94 million, a price-to-earnings ratio of -2.08 and a beta of 0.51. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $10.42. The stock's 50-day moving average price is $4.51 and its two-hundred day moving average price is $4.76.

Insider Buying and Selling

In related news, major shareholder Equity Ab Frankenius purchased 62,972 shares of TriSalus Life Sciences stock in a transaction that occurred on Tuesday, December 17th. The shares were bought at an average price of $3.97 per share, with a total value of $249,998.84. Following the purchase, the insider now directly owns 6,230,748 shares of the company's stock, valued at approximately $24,736,069.56. This represents a 1.02 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders acquired 70,012 shares of company stock valued at $281,235. Insiders own 32.80% of the company's stock.

Institutional Investors Weigh In On TriSalus Life Sciences

Several large investors have recently added to or reduced their stakes in TLSI. Walleye Capital LLC purchased a new position in shares of TriSalus Life Sciences during the third quarter valued at $66,000. Virtu Financial LLC purchased a new position in TriSalus Life Sciences during the 3rd quarter valued at about $92,000. Vestcor Inc bought a new stake in shares of TriSalus Life Sciences in the 3rd quarter valued at about $108,000. MSD Partners L.P. bought a new stake in shares of TriSalus Life Sciences in the 3rd quarter valued at about $184,000. Finally, Geode Capital Management LLC lifted its position in shares of TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company's stock worth $924,000 after purchasing an additional 62,542 shares during the period. 2.58% of the stock is owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.